Literature DB >> 6475745

Total and cardiovascular mortality in relation to cigarette smoking, serum cholesterol concentration, and diastolic blood pressure among black and white males followed up for five years.

J D Neaton, L H Kuller, D Wentworth, N O Borhani.   

Abstract

The Multiple Risk Factor Intervention Trial screening program provided an opportunity (1) to study the association of diastolic blood pressure level, serum cholesterol concentration, and cigarettes per day with all-cause and cause-specific mortality after 5 years among 23,490 black males and (2) to compare these associations with those observed among 325,384 white males. The relationship of serum cholesterol concentration and reported cigarettes per day to all-cause, coronary heart disease (CHD), and cerebrovascular disease mortality was similar for black and white males. Diastolic blood pressure was more positively associated with cerebrovascular disease death among black males than white males (p = 0.047) according to logistic regression analysis. The lower CHD mortality among black males compared to white males was most apparent among hypertensive males (diastolic blood pressure greater than or equal to 90 mm Hg). The relative risk (black vs white) of CHD death adjusted for age, serum cholesterol concentration, and cigarettes per day was 0.69 for hypertensive males compared to 1.15 for nonhypertensive males (p = 0.012 for difference in relative risk estimates). These findings suggest that the causes of CHD and cerebrovascular disease may be different for black and white males, particularly in regard to how these disease processes relate to blood pressure.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6475745     DOI: 10.1016/0002-8703(84)90669-0

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


  42 in total

1.  African-American teen smokers: issues to consider for cessation treatment.

Authors:  E T Moolchan; I Berlin; M L Robinson; J L Cadet
Journal:  J Natl Med Assoc       Date:  2000-12       Impact factor: 1.798

2.  Issues of clinical trial design and data interpretations in hypertension.

Authors:  L H Kuller
Journal:  Curr Hypertens Rep       Date:  1999-08       Impact factor: 5.369

3.  Dietary and pharmacologic management of cholesterol.

Authors:  B M Rifkind
Journal:  Tex Heart Inst J       Date:  1990

Review 4.  Effects of drugs on glucose tolerance in non-insulin-dependent diabetics (Part II).

Authors:  S O'Byrne; J Feely
Journal:  Drugs       Date:  1990-08       Impact factor: 9.546

5.  Lifetime risks of cardiovascular disease.

Authors:  Jarett D Berry; Alan Dyer; Xuan Cai; Daniel B Garside; Hongyan Ning; Avis Thomas; Philip Greenland; Linda Van Horn; Russell P Tracy; Donald M Lloyd-Jones
Journal:  N Engl J Med       Date:  2012-01-26       Impact factor: 91.245

6.  Race/ethnicity, income, major risk factors, and cardiovascular disease mortality.

Authors:  Avis J Thomas; Lynn E Eberly; George Davey Smith; James D Neaton; Jeremiah Stamler
Journal:  Am J Public Health       Date:  2005-07-07       Impact factor: 9.308

7.  Plasma cholesterol concentration and death from coronary heart disease: 10 year results of the Whitehall study.

Authors:  G Rose; M Shipley
Journal:  Br Med J (Clin Res Ed)       Date:  1986-08-02

8.  Prevalence of cardiovascular disease risk factors in blacks and whites: the Minnesota Heart Survey.

Authors:  J M Sprafka; A R Folsom; G L Burke; S A Edlavitch
Journal:  Am J Public Health       Date:  1988-12       Impact factor: 9.308

Review 9.  Coronary artery disease in black Americans 1920-1960: the shaping of medical opinion.

Authors:  R L Peniston; O S Randall
Journal:  J Natl Med Assoc       Date:  1989-05       Impact factor: 1.798

10.  Dietary chitosan enhances hepatic CYP7A1 activity and reduces plasma and liver cholesterol concentrations in diet-induced hypercholesterolemia in rats.

Authors:  Min-Sun Moon; Mak-Soon Lee; Chong-Tai Kim; Yangha Kim
Journal:  Nutr Res Pract       Date:  2007-09-30       Impact factor: 1.926

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.